Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Lymphoid 1Dermatologic 1

Conditions

Depression 4Neoplasms 3Neoplasm Metastasis 3Anxiety Disorders 3Pancreatic Neoplasms 1Ovarian Neoplasms 1Osteosarcoma 1Opioid-Related Disorders 1Melanoma 1Lymphoma 1Hospice 1Hematopoietic and Lymphatic System Neoplasm 1Hematologic Neoplasms 1Gastrointestinal Neoplasms 1Endocrine Gland Neoplasms 1Depressive Disorder, Major 1Depressive Disorder 1Caregiver Distress 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Biliary Tract Neoplasms 1Agnosia 1

Interventions

selpercatinib 2temsirolimus 1repotrectinib 1Valproic Acid 1Sirolimus 1Psilocybin 1Phlebotomy 1Immunoglobulin G 1Etoposide 1Disulfides 1Cyclophosphamide 1Cetuximab 1Biopsy, Large-Core Needle 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Endocrine Gland Neoplasms × Psilocybin × 1 year × Clear all
NCT06416085 2026-03-05

Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Patients With Advanced Cancer

University Health Network, Toronto

Phase 2 Active not recruiting
15 enrolled
DermatologicLymphoidSarcoma

Endocrine Gland Neoplasms, Lymphoma, Melanoma, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡